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Introduction: Intraspinal grafting of human neural stem cells represents a promising approach to promote
recovery of function after spinal trauma. Such a treatment may serve to: I) provide trophic support to improve
survival of host neurons; II) improve the structural integrity of the spinal parenchyma by reducing syringomyelia
and scarring in trauma-injured regions; and III) provide neuronal populations to potentially form relays with host
axons, segmental interneurons, and/or α-motoneurons. Here we characterized the effect of intraspinal grafting of
clinical grade human fetal spinal cord-derived neural stem cells (HSSC) on the recovery of neurological function in a
rat model of acute lumbar (L3) compression injury.
Methods: Three-month-old female Sprague–Dawley rats received L3 spinal compression injury. Three days post-
injury, animals were randomized and received intraspinal injections of either HSSC, media-only, or no injections. All
animals were immunosuppressed with tacrolimus, mycophenolate mofetil, and methylprednisolone acetate from
the day of cell grafting and survived for eight weeks. Motor and sensory dysfunction were periodically assessed
using open field locomotion scoring, thermal/tactile pain/escape thresholds and myogenic motor evoked
potentials. The presence of spasticity was measured by gastrocnemius muscle resistance and electromyography
response during computer-controlled ankle rotation. At the end-point, gait (CatWalk), ladder climbing, and single
frame analyses were also assessed. Syrinx size, spinal cord dimensions, and extent of scarring were measured by
magnetic resonance imaging. Differentiation and integration of grafted cells in the host tissue were validated with
immunofluorescence staining using human-specific antibodies.
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Results: Intraspinal grafting of HSSC led to a progressive and significant improvement in lower extremity paw
placement, amelioration of spasticity, and normalization in thermal and tactile pain/escape thresholds at eight
weeks post-grafting. No significant differences were detected in other CatWalk parameters, motor evoked
potentials, open field locomotor (Basso, Beattie, and Bresnahan locomotion score (BBB)) score or ladder climbing
test. Magnetic resonance imaging volume reconstruction and immunofluorescence analysis of grafted cell survival
showed near complete injury-cavity-filling by grafted cells and development of putative GABA-ergic synapses
between grafted and host neurons.
Conclusions: Peri-acute intraspinal grafting of HSSC can represent an effective therapy which ameliorates motor
and sensory deficits after traumatic spinal cord injury.
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Extensive experimental and clinical data show that the
mechanisms leading to a clinically-defined loss of neuro-
logical function after spinal trauma can in general be
considered in two categories. First is the pathology and
corresponding functional loss resulting from a direct
mechanical injury of axons at the injury epicenter, and
second is a progressive appearance of secondary changes
(local edema, hematoma, excitotoxicity and ischemia)
which can evolve over hours to weeks after the initial
impact (for review see Hagg and Oudega [1]). Consistent
with our current knowledge of the mechanism which
leads to the development of secondary post-injury cas-
cade, the current experimental and clinical treatment
strategies primarily focus on: I) improvement of local
metabolism and blood flow (for example, through de-
compression therapy and hypothermia) [2,3]; and II)
modulation of local inflammatory response (for example,
with methylprednisolone) [4-7]. A separate group of ex-
perimental treatment modalities is aimed at improving
the local neurotrophic activity at and around the injury
epicenter with the primary goal of increasing the sur-
vival of partially injured axons and/or neurons. In this
category of experimentation, besides the use of locally
delivered trophic factors (such as brain-derived neuro-
trophic factor (BDNF)-, glial cell line-derived neuro-
trophic factor (GDNF)-, and fibroblast growth factor
(FGF)-peptides or growth factors-gene-encoding vectors)
[8], regionally grafted fetal or embryonic stem cell-
derived neuronal precursors are frequently used [9-18].
Recently, well-defined protocols were developed which
permit the isolation and long-term stable expansion of
(non-immortalized) human fetal brain or spinal cord
tissue-derived neural stem cells [19-24]. Using these pro-
tocols, continuing neurogenic potential, as evidenced by
neuronal differentiation and the ability of differentiated
neurons to generate action potentials in vitro, was do-
cumented at even high (>20) passage numbers [24,25].
Some of these lines were successfully used for: I) ge-
neration of good manufacturing practice (GMP)-gradeclonally-derived cell lines; II) extensive pre-clinical evalu-
ation using a variety of neurodegenerative small and large
animal models; and III) subsequently used successfully in
Phase I human clinical trials [26-28].
In our previous studies, we have extensively characte-
rized the in vivo treatment effect after spinal grafting of
(clinical) GMP (cGMP)-grade human fetal spinal cord-
derived stem cells (NSI-566RSCs line) using a spinal
ischemia model in rats and transgenic rat model of
amyotrophic lateral sclerosis (ALS) (SOD1G93A). In those
studies, we have shown that: I) grafting of NSI-566RSCs
into lumbar spinal cord of adult Sprague–Dawley (SD)
rats with previous spinal ischemic injury is associated
with a progressive improvement of ambulatory function
which correlates with long-term grafted cell survival and
extensive neuronal differentiation [29]; and II) bilateral
lumbar grafting of NSI-566RSCs in pre-symptomatic
SOD1G93A rats provides a transient functional benefit
and suppression of α-motoneuron degeneration, that is,
a protective effect which was absent in media-injected
animals [30]. Using the same cell line, we have also dem-
onstrated the optimal dosing regimen and safety after
grafting into the lumbar spinal cord of immunosup-
pressed minipigs [29]. The dosing design defined in this
pre-clinical minipig study was then subsequently used in
a recently completed Phase I human clinical trial in ALS
patients receiving lumbar and cervical grafts of NSI-
566RSCs [27,31]. In a more recent study using an im-
munodeficient rat model of complete spinal cord Th3
transection, it was shown that NSI-566RSCs or rat em-
bryonic neural precursor cells, embedded in a fibrin
matrix with trophic factors and grafted one week after
injury, were able to form functional relays. The forma-
tion of functional relays was validated behaviorally (BBB
locomotor score), electrophysiologically (spinal cord
evoked potentials), and histologically (host on graft and
graft on host synapses) [32].
The goal of our present study was to characterize the
effect of NSI-566RSCs grafted spinally in a clinically
relevant L3 spinal compression model in continuously
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treatment effect was assessed by analysis of I) motor and
sensory function, II) myogenic motor evoked potentials
(MEPs), III) spasticity response during computer-controlled




All animal studies were approved by the University of
California, San Diego Institutional Animal Care and UseFigure 1 Schematic diagram of experimental design. A: To induce spin
segment and the spinal cord compressed in the dorso-ventral direction for
assigned to experimental groups and received a spinal graft of HSSC or me
epicenter and adjacent areas (see Spinal Injection Map). C: After spinal inje
immunosuppressed and periodically tested for recovery of motor/sensory fu
muscle spasticity response evoked by computer-controlled ankle rotation. D:
PFA and spinal cord MRI-imaged in situ before histological processing. E: Aft
spinal blocks prepared for plastic embedding (injury epicenter region) or cry
just above and below the injury epicenter). HSSC, human fetal spinal cord-de
PFA, paraformaldehyde.Committee (Protocol No.: S01193). The study design is
outlined in Figure 1. Twelve-week-old Female SD rats
were used. The rationale for choosing female rats was
based on our previous experience which demonstrates
better tolerability of female rats to spinal trauma-related
side effects, such as urinary retention. Animals were
anesthetized with isoflurane (5% induction, 1.5% to 2%
maintenance; in room air) and placed into a Lab Stand-
ard Stereotaxic frame (Stoelting, Cat# 51600, Wood
Dale, IL, USA). The animal was elevated 2 cm by placing
it on a homeothermic heating blanket (set at 37°C withal cord injury, a 35 g circular rod was placed on the exposed L3 spinal
15 minutes. B: Three days after injury, the animals were randomly
dia only. A total of 12 injections were performed targeting the injury
ctions, the animals survived for two months while being continuously
nctions, changes in motor evoked potentials (MEPs) and gastrocnemius
At two months after treatment, animals were perfusion fixed with 4%
er MRI imaging, spinal cords were dissected from the spinal column and
ostat sectioning and used for immunofluorescence staining (the regions
rived neural stem cells; MRI, magnetic resonance imaging;
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Cat# 507214, Holliston, MA, USA) which sits on a plastic
rectangular block. The animal was then placed in Spine
Adaptors (Stoelting, Cat# 51695, Wood Dale, IL, USA)
and a wide Th13 laminectomy was performed using an
air-powered dental drill and binocular microscope (expo-
sing the dorsal surface of spinal segment L3). An acrylic
rod (Ø 2.9 mm, length 15 cm; 35 g) was then slowly
lowered onto the exposed L3 segment until it slightly
touched the spinal cord but without inducing any com-
pression. The laminectomy site was then filled with
mineral oil in which the tip of a small thermocouple
(Physitemp, Cat# IT-14, Clifton, NJ, USA) was submerged
and touched the dura. The light from the two fiber optic
light pipes of the surgical light (Fiber-Lite, Cat# MI-150 &
BGG1823M, Dolan-Jenner, Boxborough, MA, USA) was
focused on the surgical site (and directly illuminating the
temperature probe). Next, the light intensity was manually
regulated so that the spinal cord/mineral oil was warmed
to 37°C and remained at 37 ± 0.3°C. If necessary, a 100 W
infrared lamp was used to gradually adjust and maintain
the animal’s core temperature at 37°C (rectal). When both
temperatures (that is, paraspinal and rectal) were at 37 ±
0.3°C for at least five minutes, the rod was slowly lowered
until its weight fully rested, perpendicularly, on the spinal
cord. The rod was kept in place for 15 minutes, while both
temperatures were maintained at 37 ± 0.3°C. After spinal
compression, the rod and mineral oil were removed and
the wound sutured in anatomical layers.
Post-surgical care
Buprenorphine (0.05 mg/kg, s.c., Reckitt Benckiser,
Richmond, VA, USA), 5 mL of lactated Ringer’s, 10 mg/kg
of cefazolin (Novaplus/Sandoz, Holzkirchen, Germany)
and standard triple antibiotic ointment to cover the inci-
sion site (bacitracin, neomycin, Polymyxin B) was given
after every surgery. Bladders were manually emptied twice
daily (if full). Sulfamethoxazole and trimethoprim USP
oral suspension (200 mg and 40 mg per 250 mL drinking
water, Hi-Tech Pharmacal, Amityville, NY, USA) was
given for at least 10 to 14 days after spinal cord injury
(SCI) or until autonomic bladder voiding occurred and for
1 to 2 days after any other surgery (sham or grafting).
Food was provided by placing it at the bottom of cage and
water bottles with an elongated drinking tube were used,
until regular overhead supplies could be reached by
the animal. Animals diagnosed with bacterial infec-
tions throughout the study were treated with sulfa-
methoxazole (as above), 10 mg/kg/day of cefazolin,
and lactated Ringer’s 5 mL/0.5 day.
Cell derivation and preparation
The cells, named ‘NSI-566RSC’, were produced by
Neuralstem Inc. (Rockville, MD, USA), as describedbefore [33]. Briefly, human spinal cord neural precursors
(HSSC) were prepared from the cervical-upper thoracic
region obtained from a single eight week fetus. The fetal
tissue was donated by the mother in a manner fully com-
pliant with the guidelines of NIH and FDA and approved
by an outside independent review board and by the Uni-
versity of California, San Diego Human Research Protec-
tion Program (Project# 101323ZX). Meninges and dorsal
root ganglia were removed and dissociated into a single
cell suspension by mechanical trituration in serum-free,
modified N2 media (human plasma apo-transferrin, re-
combinant human insulin, glucose, progesterone, putres-
cine, and sodium selenite in (Dulbecco’s) modified Eagle’s
medium ((D)MEM)/F12). For growth of the HSSC, 10 ng/
ml basic fibroblast growth factor (bFGF) was added to the
modified N2 media and expanded serially as a monolayer
culture on poly-D-lysine and fibronectin [34]. Approxi-
mately 6.1 × 106 total cells were obtained upon the initial
dissociation of the spinal cord tissue. The growth medium
was changed every other day. The first passage was con-
ducted 16 days after plating. At this point, the culture was
composed mostly of post-mitotic neurons and mitotic
HSSC. Mainly the mitotic cells were harvested through
brief treatment with trypsin and subsequent use of soy-
bean trypsin inhibitor. The cells were harvested at ap-
proximately 75% confluence, which occurred every five to
six days (20 passages). At various passages, the cells were
frozen in the growth medium plus 10% dimethyl sulfoxide
at 5 to10 × 106 cells/ml. The frozen cells were stored in li-
quid nitrogen. Upon thawing, the overall viability and re-
covery was typically 80% to 95%. A cell bank of passage 16
cells was prepared and used for this study.
For the production of eGFP-labeled NSI-566RSC, a
Lentiviral vector was constructed containing the human
Ubiquitin C promoter driving expression of enhanced
GFP. Viral particles produced by infected 293FT cells
were collected after overnight incubation, then concen-
trated by centrifugation and stored frozen. Neural stem
cell cultures were infected by overnight incubation in
growth medium supplemented with viral supernatant.
Infected stem cells were washed with phosphate-buffered
saline (PBS) and cultured as described above. After
multiple passages, >90% of the cells were GFP posi-
tive (assessed after immunohistochemical staining). A
cell bank of passage 17 cells was prepared and used
for this study.
One day prior to each grafting day, one cryopreserved
vial of the previously prepared cells was thawed, washed,
concentrated in hibernation buffer, and shipped from
the cell preparation site (Neuralstem, Inc., Rockville,
MD, USA) to the surgery site (University of California,
San Diego, CA, USA) at 2 to 8°C by overnight delivery.
Upon receipt the following day, the cells were used di-
rectly for implantation without further manipulation.
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measured with trypan blue (0.4%; Sigma-Aldrich, St.
Louis, MO, USA). Typically, a >85% viability rate was
recorded.
Inclusion and exclusion criteria, randomization and
blinding
Three days following SCI and prior to grafting, animals
were randomly divided into three groups: the vehicle-
injected group, non-injected group, or the HSSC-injected
group. SCI animals with an open-field locomotion score
of ≤1 and appearing healthy enough were included. Ani-
mals found moribund or automutilating at any point dur-
ing the study were excluded and euthanized. A total of 42
animals were employed and divided into 6 experimental
groups, as follows:
Group A (n = 14): SCI animals-NSI-566RSC-grafted,
Group B (n = 10): SCI animals-vehicle-injected,
Group C (n = 8): SCI animals-non-injected,
Group D (n = 6): sham operated (laminectomy only),
Group E (n = 6): naïve animals (no surgical
manipulation)
Group F (n = 2): SCI athymic animals-ubiquitin.eGFP+
NSI-566RSCs-grafted.
One animal was excluded in Group A because of
automutilation of the hind paw; two animals were ex-
cluded in Group C, one because of automutilation of the
hind paw and one because of bacterial infection. Six ani-
mals had been replaced before dosing/randomization,
five due to inadequate injuries and one because of bac-
terial infection.
Grafting procedure
For the intraparenchymal injections, the animals were
placed in the stereotactic frame as described above. The
L3 spinal cord (that is, the dura mater) was then re-
exposed at the previous laminectomy site. Injections
were performed using a 33 gauge beveled needle and
100 μL Nanofil syringe (World Precision Instruments,
Cat# NF33BV and Nanofil-100, Sarasota, FL, USA) con-
nected to a microinjection unit (Kopf Instruments, Cat#
5000 and 5001, Tujunga, CA, USA). The duration of
each injection was ≥45 seconds followed by a ≥30 sec-
ond pause before slow needle withdrawal. The center of
the injection was targeted intermediate of the ventral
and dorsal horn and close to the lateral funiculus (dis-
tance from the dorsal surface of the spinal cord at the
L3 level: 0.80 mm). Twelve injections (20,000 cells/μL)
were done; four injections (0.5 μL each, 0.8 to 1.0 mm
apart, rostrocaudally) at each lateral boundary of the
injury (eight in total), plus two (bilateral) injections
(0.5 μL each) 1.5 mm caudal from the previous, mostcaudal injections, and two injections at the core of the
epicenter (1 μL at each side of the dorsal vein, bilaterally;
see diagram in Figure 1). After the injections, the inci-
sion was cleaned with penicillin-streptomycin solution
and sutured in two layers.
Immunosuppression
Two days after injury (that is, one day before grafting), a
methylprednisolone acetate (Depo-Medrol, 10 mg/kg,
i.m.) was given, which was repeated thereafter three
times with 1 mg/kg/week i.m. Starting directly after
grafting, all animals received 1.5 mg/kg/BID s.c. of ta-
crolimus (Prograf/FK506, Astellas, Deerfield, IL, USA)
until the end of the study. For post-transplant days 0
to 10, the animals also received 30 mg/kg/day s.c. of
mycophenolate mofetil (CellCept, Genentech, CA, USA).
Immunosuppression was also given to the non-grafted
Sprague–Dawley animals (that is, the naïve, sham opera-
ted, and all SCI-control animals).
Open field locomotion testing
Locomotion recovery after spinal cord contusion injury
was monitored using a modified BBB open field locomo-
tion rating scale [35]. The BBB score was modified to re-
flect the distinct locomotor recovery stages observed
after L3 SCI. The modified score entailed eight well-
defined degrees of locomotor recovery: 0 to 1: are identi-
cal to the BBB-score, 2: is cumulative score of 2 and 3 of
the BBB score, 3: is cumulative score of 4, 5 and 6 of the
BBB score, 4: is cumulative score of 7 and 8 of the BBB
score, 5: reflects weight support with poor paw clear-
ance, 6: is broadened and/or shortened stepping, and 7:
is normal walking. In the present study, the locomotor
score was obtained before grafting and weekly after in-
jury until the end of the study (that is, 8.5 weeks post-
injury). In addition to a modified BBB score, a regular
full 21 scale BBB score was periodically assessed.
Gait analysis
The CatWalk apparatus (CatWalk 7.1, Noldus Technol-
ogy, Wageningen, The Netherlands) was used to quantify
gait parameters during walkway crossings (for example,
paw positioning, base of support, stride length, front
limb versus hind limb coordination) by footprint analysis
[36]. Animals had to walk down a horizontal glass walk-
way (109 × 15 × 0.6 cm, L × W × H), the glass of which
is illuminated along the long edge. At the end of the
walkway, animals had access to their home cage and
were given a treat upon arrival (Certified Supreme Mini-
Treats™, Cat# F05472-1, Frenchtown, NJ, USA). The
light only enters the (side of the) glass and reflects
merely internally (when the glass is bordered by air). As
an animal walks on the glass walkway, light reflects
off of the animal’s paws, producing a series of bright
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the walkway. The illuminated footprints were then re-
corded by a video camera with a wide-angle objective
that was located underneath the elevated glass walkway.
In order to get an optimal contrast between the paws
and the surroundings; the test was performed in a room
that was totally darkened. The animals were trained for
smooth walkway crossing on the five days prior to the
video acquisitions. To obtain accurate and meaningful
data, the following criteria concerning walkway crossings
needed to be met: (1) the animal needed to walk un-
interrupted across the walkway, at a constant pace and
(2) a minimum of three such crossings per animal were
required. Animals without bilateral paw clearance could
not be analyzed (n = 4 control-SCI animals, and 3
HSSC-treated animals). Digital data analysis consisted of
assigning labels (left-fore, left-hind, right-fore, or right-
hind) to the animal’s paw prints in a recorded walkway
crossing, using dedicated CatWalk software. Next, the
software calculated gait parameters. Data from three
proper crossings were averaged for statistical analysis.
Inclined ladder test
The inclined ladder test was performed as described be-
fore [37,38]. An inclined ladder (55°) with twenty 120
mm wide rungs (diameter: 1/4″), spaced at equal inter-
vals (60 mm) and having 150 mm-high side walls was
used. The rats were trained for this test so that smooth
runs were recorded. At the end of the ladder, the ani-
mals had access to their home cage and received a treat
(as above). The rats were placed at the bottom, and in
front, of the ladder. The bottom of the ladder was placed
on a 20 cm elevated platform. Climbing was video
recorded from a position below the ladder, so that the
ventral aspect of the animal is recorded. All animals
were able to climb up the ladder. The correct placing of
a hind paw and sustained position until its next forward
move was counted over 18 rungs (placement on first
and last rung were not counted).
Single frame hind limb motion analysis
Two parameters were measured in bilateral video cap-
tures of animals crossing a runway: the foot-stepping
angle (FSA) and the rump-height index (RHI), as de-
scribed before [37,38]. The FSA is the angle at which the
hind paw is placed on the ground just after the swing
phase. The angle is defined by a line parallel to the dor-
sal surface of the paw and a horizontal line behind the
paw. Four to six measurements were made for each hind
limb (a total of 8 to 12 step cycles). The RHI was defined
as the highest point of the base of the tail during the
(recorded part of the) run. The values for the left and
right paw of each animal were averaged. The elevated
runway bar was made of a wooden plate/beam (1500 ×150 × 20 mm, L × W × H). The animals were trained to
smoothly walk the beam. Once more, at the end of the
beam the animals had access to their home cage and re-
ceived a treat (as above). The videos (that is, the selected
frames) were selected and analyzed using the video tool
VirtualDub 1.9.11 (Written by Avery Lee, http://www.
virtualdub.org) and the on-screen measurement tool
Screen Ruler V1.0.1a (http://www.caveworks.net).
Myogenic motor evoked potentials
Animals were anesthetized with ketamine (80 mg/kg i.p.,
Ketaset, Fort Dodge Animal Health, Overland Park, KS,
USA). Myogenic motor evoked potentials (MEPs) were
elicited by transcranial electrical stimulation (with a
pulse duration of 1 ms at 7 mA using a DS3 constant
current isolated stimulator (Digitimer LTD., Welwyn
Garden City, UK) of the motor cortex using two percutan-
eously placed 30G stainless steel stimulation electrodes.
Responses were recorded from the gastrocnemius muscle
using 30G platinum transcutaneous needle electrodes
(distance between recording electrodes approximately 1
cm; Grass Technologies, Astro-Med, Inc., West Warwick,
RI, USA). Recording electrodes were connected to an ac-
tive headstage (3110 W Headstage, Warner Instruments
LLS, Hamden, CT, USA) and signal amplified using a
DP-311 differential amplifier (Warner Instruments LLS).
An amplified signal was acquired by the PowerLab 8/30
data acquisition system (AD Instruments, Inc., Colorado
Springs, CO, USA) at a sampling frequency of 20 kHz,
digitized and stored in a PC for analysis. MEPs were mea-
sured until the three to five highest (stable) recorded po-
tentials were similar. Those traces were averaged per
animal and multiplied by one thousand (μV; all values >1).
Next, for data normalization, a logarithmical transform-
ation was applied for further analysis (amplitudes of MEP
traces tended to vary much more in animals with higher
MEPs amplitudes).
Measurement of muscle spasticity
At 1.5 weeks and 2 months post-injury, the presence of
muscle spasticity in the lower extremities was measured
using a previously described system [39]. Briefly, fully
awake animals were placed in a restrainer and a hind-
paw was taped to a rotational metal plate driven by a
computer-controlled stepping motor. The metal plate is
interconnected loosely to the ‘bridging’ digital force
transducer (LCL454G, 0–454 g range; Omega, Stamford,
CT, USA). The resistance of the ankle to dorsiflexion
was measured during stepping motor-driven ankle dor-
siflexion (40°; MDrive 34 with onboard electronics; mi-
crostep resolution to 256 microsteps/full step; Intelligent
Motion Systems, Marlborough, CT, USA) at three diffe-
rent ankle-rotational velocities (40, 60 or 80°/second).
The electromyography (EMG) signal was recorded from
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time frame. To record EMG activity, a pair of tungsten
electrodes was inserted percutaneously into the gastro-
cnemius muscle 1 cm apart. EMG signals were bandpass
filtered (100 Hz to 10 kHz) and recorded before, during,
and after ankle dorsiflexion. EMG responses were re-
corded with an alternating current-coupled differential
amplifier (model DB4; World Precision Instruments,
Sarasota, FL, USA). EMG was recorded concurrently
with ankle resistance measurements, both with a sample
rate of 1 kHz. Both muscle resistance and EMG data
were collected directly to the computer using custom
software (Spasticity version 2.01; Ellipse, Kosice, Slovak
Republic). Each recorded value was the average of three
repetitions. The presence of spasticity response was
identified as an increased ankle resistance and concur-
rent increase in recorded EMG activity during com-
puter-controlled ankle dorsiflexion. To measure the
contribution of the ‘mechanical’ component in the mea-
sured resistance (that is, caused by ankle ankylosis in
chronically paraplegic animals), animals were anesthe-
tized with isoflurane at the end of each recording session
and the relative contribution of the neurogenic (that is,
isoflurane-sensitive) and the mechanical (that is, iso-
flurane non-sensitive) component identified. The magni-
tude of the anti-spasticity effect was then expressed as
the maximum possible anti-spasticity effect measured
under isoflurane anesthesia minus the value of the me-
chanical component.
Sensory testing
Recovery of sensory function was assessed through
quantification of supraspinal ‘above-level’ escape res-
ponse (AL-ER; that is, an escape or escape-attempt with
incorporation of the forelimbs) thresholds to 1) a gra-
dually increasing force to the hind paws (using the
Analgesy-Meter, no disc weights added; Cat# 37215,
Ugo-Basile, Collegeville, PA, USA), and 2) AL-ER laten-
cies to a constant heat stimulus (intensity 17, cut-off at
30 seconds) to the hind paws (using a constant infrared
heat source; Cat# 37360, Ugo-Basile,). The hind paw
tested was gently restrained by the investigator to pre-
vent withdrawal. For the heat perception test the appar-
atus was switched on ≥15 minutes prior to testing, to
allow it to warm up.
For the AL-ER tests, both hind paws were tested four
times, alternately, for each test, with a testing interval
of ≥1 hour. No more than four measurements per day
were performed, rendering two testing days per test.
Maximum cut-off values for the stimuli or latency were
at approximately two times that of the response thresh-
old of uninjured animals, to prevent tissue damage. Prior
to (one week) and during the experimental period, the
animals are extensively habituated to the experimenterso that the animals can be held upright (loosely) during
all sensory assessments. Habituation consists of picking
the animal up and holding/handling it twice daily for ≥3
minutes. Subsequently, in the absence of a stimulus,
animals only rarely showed escape behavior when held
for the time it would take to reach cut-off values. We
measured the AL-ER thresholds/latencies before injury
(baseline) and every second week after injury. The final
measurement was done at eight weeks post-injury. Two
or less (out of the total of eight, bilateral) measurements
could manually be assigned as outliers and be excluded
per time point (done while blinded for time point, ani-
mal, and treatment group). In addition, individual scores
were log transformed before analysis and we calculated
the Maximal Possible Effect, using these log scores, as
previously suggested [40]. Hence, we used the standard
formula to calculate the Maximal Possible Effect, and as-




− log xfinal of SCCI control animals
 
log xbaseline of SCCI animals
 
− log xfinal of SCCI control animals
 
Here, xy is the average AL-ER threshold of an individ-
ual animal at time point y (either for a thermal or mech-
anical stimulus).
Magnetic resonance imaging
Eight weeks after cell grafting, rats were deeply anesthe-
tized with 2 mg pentobarbital and 0.25 mg phenytoin
(0.5 mL of Beuthanasia-D, Intervet/Schering-Plough
Animal Health Corp., Union, NJ, USA) and transcar-
dially perfused with 200 ml of heparinized saline fol-
lowed by 250 ml of 4% paraformaldehyde (PFA) in PBS.
A 3 cm piece of the vertebral column (Th8-L1) was
placed in a tight small latex container filled with 4% PFA
to prevent the formation of air bubble/tissue interface
artifacts. Samples were scanned using Magnetic Reson-
ance Imaging (MRI). Images were acquired using a 7
Tesla Bruker (Bruker Biospin Billerica, MA, USA) hori-
zontal bore small animal magnet and a 2.5 cm imaging
volume transmit/receive coil. A 3D turboRARE se-
quence was used with the following imaging parameters:
echo time/repetition time 45/1500 ms, flip angle 180
degrees, field of view 16 × 16 × 16 mm, matrix 256 ×
256 × 70 with a resulting voxel size of 62 × 62 × 229 mi-
crons. The imaging time was 84 minutes per sample.
Volume reconstructions and calculations were done
using Amira software (Visage Imaging GmbH, Berlin,
Germany).
Axon counting in plastic semi-thin sections
After MRI imaging, spinal cords were dissected from the
spine and a transverse (1.5-mm-thick) spinal cord block
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embedding as previously described [41]. Briefly, dis-
sected tissue blocks were treated with 0.1% osmium tet-
roxide in 0.1 M non-saline phosphate buffer (pH 7.4) for
12 hours, followed by adequate rinsing in non-saline
phosphate buffer. This was followed by progressive alco-
hol dehydration according to standard procedures up to
100% ethanol, with the addition of further dehydration
in a 1:1 solution of ethanol/propylene oxide, and lastly
in 100% propylene oxide. Dehydrated blocks were then
prepared for resin infiltration by incubation in a 1:1 so-
lution of resin/propylene oxide on a rotator in a fume
hood overnight. The resin solution used consisted of:
Eponate 12, Araldite 502, dodecenyl succinic anhydride,
and 2,4,6-tri (dimethylamino-methyl) phenol (DMP-30;
Ted Pella, Inc., Redding, CA, USA), mixed in ratios of
10:10:25:1, respectively. The blocks were then trans-
ferred to 100% resin for subsequent overnight infiltration
on a rotator. Finally, the tissue blocks were embedded
using fresh resin in multi-chamber silicone rubber molds
made from a Silastic® E RVT Silicone Rubber Kit (Dow
Corning Corp., Midland Township, MI, USA). The molds
with embedded sections were placed in an oven at 60°C
for 1 day to facilitate resin polymerization. Semi-thin (1
μm) transverse sections were then cut using a microtome
(Leica Supercut RM 2065) with a 8-mm diamond knife
(Histo Diamond Knife, Cat# LM 7045, DiATOME,
Hatfield, PA, USA). The sections were mounted on slides
with distilled water and allowed to dry on a slide warmer.
Prior to staining, the slides were incubated at 60°C in an
oven for 10 to 15 minutes and then contrast-stained with
4% para-phenylene-diamine (PPD).
Mosaic images were taken of two sections per animal
at 20X using a Zeiss Imager. M2 fitted with a Zeiss
MRm camera (Carl Zeiss Microscopy, Thornwood, NY,
USA), a BioPrecision2 stage (Cat# 96S100, Ludl Elec-
tronic Products, Hawthorne, NY, USA), and Stereo Inves-
tigator software (MBF Biosciences, Williston, VT, USA).
Complete mosaic images were loaded into ImageJ 1.45s.
Axonal quantification involved manual definition of pixel
threshold (0 to 255, grayscale; using the Triangle method).
Next, ImageJ’s Analyze Particles option was used to find
particles with a size of 0.20 to 250 μm2 and a circularity of
0.5 to 1.0 (which corresponded to axons). All acquisition
and analysis values were held consistent throughout the
study. Final measurements acquired were the minimal
diameter (Feret’s) of each particle (and particle counts).
Particles with a minimum diameter >10 μm were ex-
cluded. Employment of this parameter allowed for fur-
ther axonal analysis, in which axons were divided into
empirically-derived caliber sizes of small, medium, and
large axons (0.3 to 1.0 μm, 1.0 to 2.5 μm, and 2.5 to 10
μm, respectively). Data were acquired per spinal region
(that is, dorsal, ventral, and lateral funiculi).Immunofluorescence staining
After removing the 1.5 mm block from the spinal cord
at the injury epicenter, the remaining caudal and rostral
parts of the spinal cord (±1 cm each) were placed in
30% sucrose for cryoprotection for a minimum of five to
seven days. Transverse spinal cord sections were then
prepared from the L6 segment. The segment(s) in be-
tween the L6 and the injury epicenter and the one ros-
tral to the injury epicenter were sectioned coronally and
used for identification of grafted human cells. All sec-
tions were cut on a cryostat and stored free-floating in
PBS with thimerosal (0.05 wt%). Sections were stained
overnight at 4°C with primary human-specific (h) or
non-specific antibodies in PBS with 0.2% Triton X-100:
mouse anti-nuclear mitotic apparatus (hNUMA, 1:100;
Millipore, Billerica, MA, USA), mouse anti-neuron spe-
cific enolase (hNSE, 1:500; Vector Labs, Burlingame,
CA, USA), mouse anti-synaptophysin (hSYN, 1:2,000;
Millipore), rabbit anti-glial fibrillary acidic protein
(hGFAP, 1:500; Origene, Rockville, MD, USA), mouse
anti-neuronal nuclei (NeuN, 1:1,000; Millipore), chicken
anti-GFP (1:1,000; Aves Labs, Tigard, OR, USA), rabbit
anti-anti-glutamate decarboxylase 65 and 67 (GAD65
and 67; 1:300; Millipore), mouse anti-GFAP (Cy3-labeled;
1:500; Sigma-Aldrich; St. Louis, MO, USA), rabbit
anti-Ki67 antibody (mitotic marker, 1:100; Abcam,
Cambridge, MA, USA), goat anti-doublecortin (DCX,
1:1000, Millipore), goat anti-choline acetyltransferase
(CHAT, 1:50, Millipore/Chemicon), and rat anti hu-
man axonal neurofilament antibody (hHO14; 1:100;
gift from Dr. Virginia Lee; University of Pennsylvania,
Philadelphia, PA, USA). Mouse anti-growth associated
protein 43 (GAP43, 1:16,000; Millipore), rabbit anti-
calcitonin gene-related peptide (CGRP, 1:1,000; Biotrend,
Destin, FL, USA), and rabbit anti-ionized calcium binding
adaptor molecule 1 (Iba1, 1:1,000; Wako, Richmond,
VA, USA), were used on the L6 transverse sections.
Following washing in PBS for three to five minutes,
sections were incubated with fluorescent-conjugated
secondary donkey antibodies (Alexa® Fluor 488 & 647;
1:500; Jackson Immuno Research, West Grove, PA,
USA; and Alexa® Fluor 555, 1:500; Invitrogen, Carlsbad,
CA, USA). Sections were then mounted on slides, dried
at room temperature, and covered with Prolong anti-
fade kit (Invitrogen).
Confocal images (1024 × 1024 pixels) were captured
with a Fluoview FV1000 microscope (Olympus, Center
Valley, PA, USA) with a 20X or 40X objective, optical
section spacing of 0.5 μm, and pulse speed of 20 μsec/
pixel. Other images were taken using the Zeiss Imager.
M2 setup as described above, using a 10, 20 or 63X
magnification. CGRP, GAP43, and Iba1 stainings on L6
transverse sections were quantified using densitometry
measurements of the main dorsal horn region (Laminae
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ware was used for quantification by using the Back-
ground Subtraction function.Figure 2 Significant decrease in the dorsal horn CGRP immunoreactiv
SCI-control animals. CGRP- (A), GAP-43- (B), and Iba1- (C) immunoreactivi
months after L3 SCI. The region of interest (ROI) was defined as outlined in
analysis of CGRP-immunostained images in the dorsal horns of SCI-HSSC-tr
when compared to SCI-control animals (A1). B, C: The dorsal horn GAP-43
experimental groups. (A - C: data expressed as mean ± SEM; student t-test
GAP-13, growth associated protein 43; HSSC, human fetal spinal cord-deriv
SCI, spinal cord injury.Statistical analyses
Behavioral data were analyzed using analysis of variance
(ANOVA) one-way, or two-way group × time repeatedity caudal to the injury epicenter in SCI-HSSC-treated versus
ty in the dorsal horns (DH) caudal of the injury epicenter at two
B and C (left panels, red dotted line). A: The quantitative densitometry
eated animals (A2) showed significantly decreased CGRP expression
or Iba1 immunoreactivity was not significantly different between
s). (Scale Bars: A - C: 500 μm). CRGP, calcitonin gene-related peptide;
ed neural stem cells; Iba1, ionized calcium binding adaptor molecule 1;
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post hoc test for multiple comparisons). A P value of
0.05 was considered significant. Unequal variances were
explored prior to using ANOVA analyses using the
Bartlett’s test, but were not identified. Post hoc tests were
only calculated if overall group differences were found.
Results are expressed as means with the standard error
of the mean (SEM). To analyze differences between the
two groups (for example, vehicle injected versus non-
injected SCI animals), we used Student’s t-tests (unequal
variances were explored with the F-test, but not found)
or repeated measures ANOVA. Naïve and sham oper-
ated animals were grouped (and named ‘non-injured’) in
all outcomes besides the sensory tests. All statistical ana-
lyses were done using GraphPad Prism (La Jolla, CA,
USA), SPSS statistics 17 (for K-Means clustering; IBM,
Armonk, NY, USA), or STATA 12 (for precise post-hoc
test P-value calculations; StataCorp LP, College Station,
TX, USA) and performed two-tailed.
Results
General animal health and survival of animals during
long-term immunosuppression
From the total of 35 SCI Sprague–Dawley rats employed
in this study, 32 survived until planned sacrifice while
continuously immunosuppressed; 14 NSI-566RSC-injected
(1 excluded because of automutilation of hind paw on day
two post-injury), 10 vehicle-injected, 8 non-injected
(2 excluded, 1 because of automutilation of hind paw
on day 7 post-injury and 1 because of excessive body
weight loss on post-injury day 18 (likely related to
immunosuppression-related toxicity)). In four surviving
animals, lower extremity ulcers developed but were ef-
fectively treated with local standard triple antibiotic
ointment (bacitracin, neomycin, and Polymyxin B) and
cohesive bandages. In most animals, the Crede’s man-
euver needed to be performed for three to five days
after spinal trauma (exceptions: three animals in the
NSI-566RSC-injected group and two animals in the
non-injected SCI-control group, of which one died due
to health issues; see above). No additional worsening
(that is, a lowering in open-field locomotor scores at
one day post-grafting, compared to pre-grafting values)
was noted in intraspinal media- or cell-injected animals.
Spinal injection procedure did not alter neurological
outcome in previously L3-contused rats
In order to define the effect of spinal injection itself in
modulating the functional recovery profile (that is, po-
tential worsening in neurological outcome) in L3-injured
animals, we first compared the effect of spinal media in-
jection only with spinal injury animals that received no
injections (10 vehicle-injected and 8 non-injected SCI
animals). No significant differences were found betweenthese two groups in any of the neurological or electro-
physiological outcome measures used in this study (re-
peated measures ANOVA for open field locomotor
scores; Student’s t-test for others). Based on these data,
which showed no significant differences between both
control groups, these two groups were then pooled into
one control group and used for subsequent comparison
with HSSC-grafted animals.
Assessment of motor function
Gait analysis showed significant improvement in hind paw
placement in SCI-HSSC-grafted animals
Gait analysis was conducted at eight weeks after grafting
(or corresponding time point in controls) using the
CatWalk apparatus [42]. The following parameters were
analyzed: I) runway crossing time, II) rostro-caudal
hindpaw positioning, III) hind paws base of support, IV)
regularity index/coordination, V) stride length, and VI)
phase dispersions.
Rostro-caudal hindpaw positioning (RCHPP)
In control non-injured animals, the RCHPP was 0 ± 1.7
mm (that is, the animals are able to achieve a near
complete overlap in the hindpaw positioning relative to
the last ipsilateral frontpaw print; full rostro-caudal
overlap is represented by a value of ‘0’). Rats receiving
spinal HSSC grafts showed significantly better RCHPP,
when compared to control SCI animals (−9.0 ± 1.9 ver-
sus -18.2 ± 3.1 mm, respectively, Figure 3A; Bonferroni:
P = 0.04). Examples of the paw positioning are shown in
Figure 3B for a non-injured control, SCI control, and a
HSSC-treated SCI animal (Figure 3-B1, -B2, and -B3,
respectively).
No significant differences were detected in other
CatWalk parameters (runway crossing time, hind paws
base of support, regularity index/coordination, stride
length, phase dispersions), myogenic MEPs, or behav-
ioral motor tests (open field locomotor score (modified
BBB score, and regular BBB scores), single-frame motion
analysis or ladder climbing test) (see Additional file 1:
Figure S1A-D).
Effective suppression of muscle spasticity in HSSC-grafted
SCI animals
To identify the presence of spasticity (that is, potent-
iation in muscle stretch-evoked EMG activity) in animals
after SCI, a computer-controlled ankle-rotational force
was applied on the right or left paw in fully awake re-
strained animals and the resulting change in EMG acti-
vity in the gastrocnemius muscle and correlative ankle
resistance was measured [39].
Independent of SCI group (control or HSSC-injected),
two quantitatively different EMG patterns and corre-
sponding resistance response (EMG/RES) patterns were
Figure 3 Improvement in hind paw positioning and muscle spasticity in SCI animals grafted with HSSC. A: CatWalk gait analysis of hind
paw positioning at two months after treatment. In comparison to SCI control animals, a significant improvement was seen in HSSC-grafted
animals. B1-B3: An example of paw step images taken from the CatWalk software in naïve (B1), SCI-control (B2) and SCI-HSSC-treated animals
(B3). Note a large paw footprint overlap between the front and hind paws in naïve animals (B1) but a substantial dissociation in footprint overlap
in SCI controls (B2). An improvement in paw placement in SCI-HSSC-treated animals can be seen (B3). C: Statistical analysis showed significant
suppression of spasticity response (expressed as a muscle resistance ratio: values at two months versus seven days post injury in ‘HIGH spasticity’
HSSC-treated animals if compared to ‘HIGH spasticity’ controls). D: To identify the presence of muscle spasticity in fully awake animals, the
hind-paw ankle is rotated 40° at a velocity of 80°/second. Spasticity is identified by exacerbated EMG activity measured in the gastrocnemius
muscle and corresponding increase in muscle resistance. In control SCI animals with developed spasticity (that is, ‘high spasticity’/HIGH group), no
change in spasticity response if compared to seven days post-vehicle injection was seen at two months (compare D1 to D3). In contrast to SCI
control animals, a decrease in spasticity response was seen in SCI-HSSC-treated animals at two months after cell injections (compare D4 to D6).
To identify mechanical resistance, animals are anesthetized with isoflurane at the end of the recording session and the contribution of
mechanical resistance (which is, isoflurane non-sensitive) is calculated. (D2, D5: data expressed as mean ± SEM; one-way ANOVAs). ANOVA,
analysis of variance; EMG, electromyography; HSSC, human fetal spinal cord-derived neural stem cells; SCI, spinal cord injury; SEM, standard error
of the mean.
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to control non-injured animals, little or no change in
EMG/RES response was seen at 1.5 weeks after SCI. Se-
cond, SCI induced an increased spasticity response in a
portion of the animals at 1.5 weeks after injury. A K-
Means clustering method was used to group all 44 (SCI
and non-injured) animals into two groups based on the
magnitude of resistance to ankle rotation at 1.5 weeks
post-injury (or equivalent time point in non-injured ani-
mals). Seven animals of each SCI group (that is, control
or HSSC-injected) were found to be clustered in the
high ‘spasticity’ group (HIGH), which had a 31.7 ± 3.9 g
increase in measured muscle resistance during ankle rota-
tion, compared to the low ‘spasticity’ group (LOW) show-
ing 8.9 ± 1.5 g resistance (Student’s t-test: P <0.0001). No
difference in the incidence of this high ‘spasticity’ responsewas noted between SCI control versus cell-treated groups
(incidence: Χ2: P = 0.53; extend: Student’s t-test: P = 0.24).
No naïve or sham operated animals were found to be clus-
tered in the HIGH group. Resistance to ankle rotation
measured eight weeks after treatment (and expressed as
relative change from 1.5 weeks post-injury values) showed
a significant decrease in the HSSC-injected HIGH resist-
ance group when compared to HIGH resistance animals
from the control SCI group (Figure 3C; that is, decline of
24.8 ± 6.4 g in HSSC-injected animals and 4.8 ± 6.3 in
control SCI animals; Bonferroni: P = 0.048).
Figure 3D shows an example of raw data depicting a
post injury EMG response (red channel) and corre-
sponding increase in muscle resistance (black channel)
during ankle rotation in a SCI-control (Figure 3-D1-3)
and a HSSC-injected animal (D4-6) at seven days after
Figure 4 Amelioration of hypoesthesia in SCI-HSSC-grafted
animals. Baseline and biweekly assessments of perceptive
thresholds for (A) mechanical and (B) thermal stimuli, applied below
the level of injury, showed a trend towards progressive recovery in
SCI-HSSC-grafted animals. C: When expressed as percentages of the
maximal possible effect for mechanical and thermal perceptive
thresholds improvements, SCI-HSSC-treated animals showed
significant improvements in sensory function for both mechanical
and thermal components. (A-C: data expressed as mean ± SEM; A-B:
repeated measures ANOVAs; C: Student t-tests). ANOVA, analysis of
variance; HSSC, human fetal spinal cord-derived neural stem cells;
SCI, spinal cord injury; SEM, standard error of the mean.
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Clear suppression of potentiated EMG response and
muscle resistance can be seen in HSSC-treated animals
(compare D4 to D6). To identify and dissociate neu-
rogenic (that is, isoflurane-sensitive) versus mechanical
(that is, isoflurane non-sensitive) components, muscle
resistance was re-measured after isoflurane anesthesia
and the relative contribution of the mechanical compo-
nent calculated. The induction of isoflurane anesthesia
almost completely blocked the ankle rotation-evoked
EMG response and resulting increase in muscle resist-
ance (D2, D5).
Assessment of sensory functions
Analysis of mechanical and thermal sensory function
was performed by comparing hindpaw thresholds im-
provements of evoked above-level/supra-spinal with-
drawal responses (that is, an escape response in which
the frontlimbs and/or vocalizations are used) between
experimental groups over several time points. Groups
consisted of naïve control, sham operated control, SCI-
control, or SCI-HSSC-injected animals. Response thres-
holds were measured before injury and every second
week thereafter. No differences were measured between
naïve and sham-operated animals at any time point in
response thresholds to both mechanical and thermal
stimuli (repeated measures ANOVA).
HSSC treatment led to a significant improvement in the
supraspinal perception to mechanical stimuli evoked
below the level of injury
Prior to injury, no differences in mechanical thresholds
to trigger escape responses were measured between all
four experimental groups (on average 92 ± 2 g). After
SCI, the thresholds increased significantly in both SCI-
control and SCI-HSSC-injected animals compared to con-
trol non-injured groups, at all time points (Bonferroni;
P <0.001). From four weeks post injury, SCI-HSSC-
injected animals displayed a trend towards progressive
improvement in response thresholds if compared to
SCI controls (at eight weeks: 177 ± 10 g and 216 ± 10 g,
respectively; Figure 4A; repeated measures ANOVA:
P = 0.14). This resulted in a significantly higher percent-
age of the maximal possible effect for improvement of
mechanical stimulus perception in SCI-HSSC-injected
animals compared to SCI-control animals (Figure 4C;
Student’s t-test: P = 0.03).
Treatment with HSSC was associated with significant
recovery of supraspinal heat perception evoked below
the level of injury
Prior to SCI, measurement of thermal (infrared) stimu-
lus-evoked paw withdrawal threshold showed no signifi-
cant differences among all experimental groups (17.3 ±
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significant increases in paw withdrawal latencies in both
the control SCI group and in SCI animals receiving
spinal HSSC grafts were measured, when compared to
control non-injured (sham operated and naive) groups
(26.1 ± 0.7 seconds in SCI-control animals and 26.5 ±
0.7 seconds in HSSC-grafted animals versus 18.3 ±
0.2 seconds in control non-injured animals; Figure 4B;
Bonferroni: P < 0.001).
From four weeks after treatment a trend towards a
progressive normalization in response threshold was
seen in HSSC-treated animals if compared to SCI con-
trols (at eight weeks: 24.0 ± 0.9 seconds in SCI-control
and 21.4 ± 0.9 seconds in HSSC-injected animals, re-
spectively; repeated measures ANOVA: P = 0.09). This
resulted in a significantly higher percentage of the max-
imal possible effect for the improvement of thermal
stimuli in SCI-HSSC-injected animals compared to SCI-
control animals (Figure 4C; Student’s t-test: P = 0.02).Figure 5 Effective cavity-filling effect by transplanted cells in SCI HSS
survival, animals were perfusion fixed with 4% PFA, the spinal column disse
histological processing. A, B: Three-dimensional MRI images of spinal cord
spinal HSSC (A) or media (B) injections. Note the near complete injected-ce
validate the presence of grafted cells or cavitation at the epicenter of injur
sections prepared and compared to the corresponding MRI image (compa
a naïve-non-injured animal. D: Quantification of the cavity and scar volume
volumes in SCI-HSSC-injected animals if compared to media-injected SCI co
A, B: 5 mm; A1, A2, B1, B2, C: 3 mm). HSSC, human fetal spinal cord-derive
paraformaldehyde; SCI, spinal cord injury; SEM, standard error of the mean.Postmortem spinal cord MRI showed a cavity-filling effect
by grafted cells in HSSC-injected animals
For lesion volume analyses, a 3-cm long portion of the
fixed spinal column was dissected out, kept in 4% PFA
and imaged using a 7 Tesla MRI magnet. The primary
goal of this analysis was to generate quantitative data on
the cavity-filling effect by grafted cells and to assess the
extent of rostro-caudal cavitation in vehicle-injected ver-
sus HSSC-injected animals using quantitative volume
analysis (Figure 5). In vehicle-injected animals, the pres-
ence of fluid-filled cavities was readily identified as the
presence of homogenous white areas and scarring as
black areas (Figure 5B1; compare with non-injured:
Figure 5C). In contrast, in animals receiving cell injec-
tions, the cavity was partially or completely filled with
grafted cells as evidenced by the presence of low density
tissue masses (Figure 5A1). The identity/presence of
grafted cells in the ‘low density tissue masses’ was fur-
ther validated by analysis of semi-thin plastic sectionsC-injected animals. At the end of the two-month post-treatment
cted and MRI-imaged in situ before spinal cord dissection for further
segments in animals with previous traumatic injury and treated with
lls cavity-filling effect in HSSC-treated animals. A1, A2, B1, B2: To
y, the same region was histologically processed, semi-thin plastic
re A1 to A2 and B1 to B2). C: Two-dimensional MRI image taken from
from serial MRI images showed significantly decreased cavity and scar
ntrols. (D: data expressed as mean ± SEM; Student t-tests), (Scale Bars:
d neural stem cells; MRI, magnetic resonance imaging; PFA,
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depicts the presence of cell grafts versus extensive cavity
in Figure 4B2). Figure 5A shows a three-dimensional
reconstruction image of a cell-injected animal (areas
identified as grafted cells are labeled green). Figure 5B
shows a SCI-control (media-injected) animal with cav-
ity labeled in light-green-yellow.
Quantification of the cavity volume showed a sig-
nificantly larger injury-induced cavity in SCI-control
animals than in HSSC-injected animals (3 ± 0.4 mm3
versus 0.6 ± 0.2 mm3, respectively; Figure 5D; Student’s
t-test: P <0.0001). Similarly, the scar volume seen in
SCI-control animals was larger than in cell-injected ani-
mals (3.3 ± 0.3 mm3 versus 1.9 ± 0.3 mm3, respectively;
Student’s t-test: P <0.001).
To assess the potential excessive grafted cell prolifera-
tion and resulting spinal cord tissue expansion, we next
compared the total volume (that is, the volume of the
remaining spinal cord, scar, cavity, and/or grafted cells)
of the cell-grafted spinal cord segments with the corre-
sponding segments of the control animals. The mea-
sured volumes were: 71.8 ± 3.2 mm3 in non-injured
control animals, 54.6 ± 2.8 mm3 in SCI-control ani-
mals, and 59.0 ± 2.2 mm3 in SCI-HSSC-injected ani-
mals (Student’s t-test: P = 0.27; SCI-control versus
SCI-HSSC-injected animals).
Survival, maturation and integration of grafted HSSC
To identify the presence of human cells in the rodent
spinal cord tissue, two different immunostaining/analy-
tical methods were used. First, eGFP-tagged grafted cells
were identified by the presence of GFP autofluorescence/
immunoreactivity and then co-stained with neuronal and
non-neuronal markers. Second, a set of human-specific
antibodies was first used to validate the presence of
human cells and then combined with other human-non-
specific neuronal or non-neuronal antibodies.
Staining with anti-GFP, -NeuN (neuronal marker) and -
human-specific synaptophysin antibody showed a near
complete repopulation of the compression-induced lesion
cavity by grafted GFP + cells (Figure 6A-yellow dotted
area). A comparable spinal injury-cavity filling by grafted
cells was seen after grafting with eGFP or non-labeled
HSSC as evidenced by the presence of dense hNUMA-
immunoreactive grafts (Figure 6A inserts). Analysis of
axo-dendritic sprouting from grafted GFP+ cells showed
that extensive rostro-caudal neurite sprouting was particu-
larly well-developed in the lateral white matter (Figure 6B).
In addition, numerous GFP+ axons branching from
innervated lateral funiculi and projecting towards α-
motoneurons and interneurons were identified (Figure 6B;
insert). Triple staining with NeuN, hSYN and GFP anti-
body showed a high density of hSYN punctata in GFP+
innervated regions (Figure 6C - yellow arrows) as wellas in the vicinity of endogenous NeuN+ neurons. Stain-
ing with hNUMA, hNSE and DCX antibody revealed
that the majority of hNUMA+ grafted cells were DCX
or DCX/hNSE immunoreactive (Figure 6A - insert;
Figure 6D). Probing for glial phenotype in grafted cells by
double staining with hNUMA and hGFAP or hNUMA
and Olig2 antibody revealed well-developed groups of
hGFAP+ astrocytes. These GFAP+ cell populations were
primarily found in the white matter or at the periphery
of individual DCX/hNSE+ grafts (Figure 6E). Less than
2% of hNUMA+ cells showed Olig2 immunoreactivity
(Figure 6F; yellow arrows). To assess the presence of
mitotically active grafted cells, sections were double-
stained with hNUMA and Ki67 antibody. An estimated
0.5% to 1% of hNUMA+ cells were Ki67 positive. These
double hNUMA/Ki67+ cells were regularly distributed
throughout the grafted regions but no cluster(s)-like
formations of hNUMA/Ki67+ cells were seen in any
animal (Figure 6G; yellow arrows).
Confocal analysis of spinal cord sections triple-
stained with hSYN, GFP and NeuN antibodies showed
numerous hSYN punctata colocalizing with GFP+ pro-
cesses. Several hSYN punctata were found to reside in
the vicinity of interneuronal and/or α-motoneuronal
membranes (Figure 7A; inserts; white arrows). Probing
for the presence of GAD65/67+ terminals derived from
grafted neurons by using triple stained GAD(65/67)/
GFP/NeuN sections and confocal microscopy showed
the presence of GFP/GAD65/67+ terminals in the
vicinity of α-motoneuronal membranes (Figure 7B;
white arrows).
Normalization of CGRP expression in L6 dorsal horns in
SCI-HSSC-treated animals
To analyze changes in the spinal expression of putative
central pain neuromodulators/indicators, including CGRP,
GAP43 and Iba-1 [43,44], we next stained transverse L6
sections (that is, below-injury-level region) with respec-
tive antibodies at eight weeks after treatment (Figure 2A,
B, C). Densitometry analysis showed that CGRP immuno-
reactivity was significantly reduced in SCI-HSSC-treated
animals (Figure 2 A2) when compared to SCI-controls
(Figure 2 A1; Student’s t-test: P = 0.04). We did not find
significant group differences in IHC staining inten-
sities of either GAP43 or Iba1 (Figure 2B, C; Student’s
t-test: P = 0.58 and P = 0.24, respectively).
Quantitative assessment of axonal survival in the
epicenter of injury using semi-thin plastic sections
For quantitative analysis of axonal survival, a transverse
spinal cord block taken from the injury epicenter was
used. Using osmium/p-phenylenediamine-stained semi-
thin (1-μm-thick) plastic sections, the total number of
axons (divided into three subgroups based on the axonal
Figure 6 Survival, differentiation and extensive axonal outgrowth from spinally grafted HSSC. A: Grafted GFP+ or hNUMA+ cells can be
seen almost completely filling the lesion cavity at eight weeks after grafting (yellow dotted area; inserts). B: Detail from ‘A’ depicting a dense GFP+
neurite network in the lateral funiculus (LF) and with numerous axons projecting towards α-motoneurons and interneurons in the gray matter (insert).
C: In areas with a dense GFP+ axodendritic network, clear hSYN immunoreactivity associated with GFP+ processes can be detected (yellow arrows).
D: The majority of grafted hNUMA+ cells showed development of the neuronal hNSE/DCX+ phenotype. E, F: A subpopulation of grafted hNUMA+
cells showed the astrocyte (hGFAP+) and oligodendrocyte (Olig 2) phenotype (F; yellow arrows). G: Using mitotic marker Ki67, regularly distributed
hNUMA/Ki67+ grafted cells were identified (yellow arrows). (Scale Bars: A: 1.5 mm (inserts: 200 μm); B: 600 μm (insert: 75 μm); C: 60 μm;
D: 20 μm; E-G: 10 μm). HSSC, human fetal spinal cord-derived neural stem cells; SCI, spinal cord injury.
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meter) was then counted using ImageJ software.
Systematic quantification of the total number of mye-
linated axons counted bilaterally in a control naïve
animal showed 281,352 axons (see Additional file 2:Figure S2A). Thirty-three percent was represented by
small caliber axons, 57% by medium caliber axons and
10% by large caliber axons. In SCI-control animals, the
total number of axons was on average 55,137 ± 5,168
and was 55,340 ± 5,650 in HSSC-injected animals
Figure 7 Development of putative GABA-ergic synaptic contact between HSSC and the host neurons. A: Confocal analysis of hSYN/GFP/
NeuN-stained sections shows numerous hSYN punctata associated with GFP+ processes derived from grafted cells. Some of the hSYN/GFP+
terminals were found to be in the vicinity of the host interneurons or α-motoneurons (A; inserts; white arrows). B: Triple staining with GAD65/67/
GFP/NeuN antibody showed numerous double-stained GAD65/67/GFP+ terminals residing on or in the close vicinity of lumbar α-motoneurons
(white arrows). (Scale Bars: A: 150 μm (inserts: 30 μm); B: 20 μm). HSSC, human fetal spinal cord-derived neural stem cells.
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Intergroup statistical analysis of the axons at specific di-
ameters (that is, 0.3 to 1.0, 1.0 to 2.5, and 2.5 to 10 μm)
showed P-values of 0.88, 0.84, and 0.51 (Student’s t-tests)between SCI-control and SCI-HSSC-grafted animals,
respectively. Intergroup statistical analysis of the axons
at specific funiculi (that is, dorsal, lateral, and ventral fu-
niculi) showed P-values of 0.73, 0.82, and 0.72 (Student’s
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mals, respectively (see Additional file 2: Figure S2D). Add-
itional intergroup analyses of axon survival categorized by
both size and location/funiculus did not show significant
differences between SCI-control and SCI-HSSC-grafted
animals (P >0.36; Student’s t-tests) (see Additional file 2:
Figure S2D).
Discussion
In the present study, we investigated the treatment effect
of spinally grafted GMP-grade HSSC in a L3 SCI model
in rats.
HSSC were grafted into and around the epicenter of
the contusion-injured L3 spinal segment at three days
after spinal trauma in continuously immunosuppressed
Sprague–Dawley rats. In comparison to control SCI ani-
mals with no treatment or receiving intraspinal injec-
tions of media only, the intraspinal grafting of HSSC led
to a progressive and significant improvement in: I) gait/paw
placement, II) muscle stretch-induced spasticity, and III)
mechanical and thermal sensitivity. These behavioral
benefits were associated with robust graft survival and
a near complete injury-cavity-filling effect with grafted
cells and corresponding lack of syringomyelia other-
wise seen in control SCI cell-non-treated animals. In
addition, the development of putative GABA-ergic
synapses between grafted neurons and interneurons
and/or α-motoneurons of the host were identified.
These data demonstrate that intraspinal grafting of
HSSC into an injured spinal cord segment in the acute
phase of injury represents a safe and effective treat-
ment modality. This cell-replacement therapy was effect-
ive in providing qualitatively- and quantitatively-defined
functional benefits and also led to significant and long-
term improvement in the structural integrity of previ-
ously trauma-injured spinal cord segments.
Rat L3 spinal compression injury model
In our current study, a lumbar spinal injury was induced
by a static 35 g pressure exerted on the dorsal surface of
the L3 spinal segment by using a stainless steel-Teflon
rod (2.9 mm in diameter). In our preliminary ‘survey’
study, we found that in this model the 35 g spinal cord
compression needs to be maintained for a minimum of
15 minutes to produce a reproducible degree of func-
tional and histopathologically-defined injury. These data
indicate that the pathophysiological mechanism leading
to neuronal/axonal degeneration in this model is primar-
ily related to the ischemia-induced changes. However,
interestingly, the histopathological changes in this mo-
del are characterized by the development of a well-
delineated cavity found just below the compression site.
This is in contrast to the ‘pure’ ischemia-reperfusion-
induced spinal injury seen in aortic balloon occlusionmodels in which a selective loss of inhibitory interneu-
rons is seen in previously ischemia-exposed spinal seg-
ments in the absence of cavity(s) formation [45,46]. In
this respect, our current model appears to be similar to
high velocity (weight drop model) impact injury models
which show comparable cavity formation in chronic L2
or L3/4 segment-injured rats [47,48]. Similarly as dem-
onstrated in the rat ‘weight drop’ contusion models
[49], the development of spinal hyper-reflexia, as evi-
denced by the presence of exacerbated muscle activity
evoked by computer-controlled ankle rotation, was seen in
a subpopulation of injured animals in our current study.
Importantly, spinal cavity formation and muscle spasticity
is frequently observed in human patients with a high-
velocity-impact-induced traumatic SCI [50,51].Rationale for early spinal cell-replacement therapy after
spinal trauma
Both experimental and clinical data show that the spinal
pathological processes following acute spinal injury are
in part characterized by continuing axonal/neuronal de-
generation, which can then continue for months to years
after injury [1,52-55]. It is believed that such an ongoing
axonal degeneration is, in part, the result of the lack of
local trophic support associated with loss of neurons/
glial cells at and around the injury epicenter. Thus, the
use of treatment strategies that can replace or supple-
ment the loss of the local neurotrophic activity and are
initiated during this acute period should thus lead to a
measurable treatment effect. Previous studies have dem-
onstrated that neural stem cells of mouse, rat or human
origin are a rich source of extracellularly released tro-
phic factors (such as NGF, BDNF, GDNF, EGF, IGF-1,
and VEGF) in in vitro cultured cells and that these cell
populations retain a high level of neurotrophin expres-
sion after in vivo grafting in naïve animals and in a var-
iety of neurodegenerative models including spinal injury
and transgenic ALS models [56-61]. In addition, using
long-term post-grafting survival periods, it was shown
that following in vivo grafting of neural precursors with
neurogenic potential into either the spinal cord at nine
days post spinal cord injury, the brain at three days post
ischemic insult, or the central nervous system (brain or
spinal cord) of adult or developing rats, there is the de-
velopment of functionally and morphologically-defined
synaptic contacts between grafted neurons and the neu-
rons of the host [62-64].
Based on these characteristics of neural precursors
(NPCs), the use of NPCs for acute spinal cord grafting
after trauma serves three purposes. First, it serves to
provide local trophic support in the areas of previous in-
jury (provided that grafted cells are able to home and
survive long-term once grafted into the injured spinal
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gressive axonal/neuronal degeneration. Second, it serves
to provide a cavity-filling effect by replacing previously
injured-degenerated necrotic tissue and, thus, prevents
the long-term (or progressive) formation of rostro-
caudal cavitations (that is, syringomyelia) [55]. Third, by
the development of synaptic contact with the host
axons/neurons above and below the injury level it can
potentially lead to formation of a functional relay through
the injury site.
Effect of spinal grafting of HSSC on the recovery of motor
function and muscle spasticity
In our current study, a combination of several motor
performance tests were employed including open field
modified BBB scoring, CatWalk gait analysis, inclined
ladder climbing, single frame hind limb motion analysis
and myogenic motor evoked potentials to identify the
degree of motor function recovery after cell grafting.
The changes in muscle spasticity in lower extremities
(that is, below the level of injury) were also measured
using a computer-controlled ankle rotational system
[39]. The CatWalk gait analysis showed significantly im-
proved paw placement in HSSC-injected SCI animals
when compared to control SCI animals. In addition, a
significant suppression of an otherwise exacerbated mus-
cle spasticity response measured during ankle rotation
was seen in cell-treated animals. However, no improve-
ments in other functional CatWalk parameters (runway
crossing time, hind paws base of support, regularity
index/coordination, stride length, phase dispersions),
MEPs, BBB score, single-frame motion analysis or ladder
climbing test) were seen. Consistent with our current
data, several other studies from different laboratories
have demonstrated a variable degree of motor function
recovery after spinal grafting of rodent or human fetal,
adult or embryonic stem-cell-derived neural precursors
using a variety of spinal injury models in mice and rat
[14,29,32,65-72]. Importantly, these data jointly suggest
that some degree of therapeutic effect can also be
achieved once cells are grafted during the early post-injury
period (that is, three to seven days after spinal trauma).
Effect of spinal grafting of HSSC on the recovery of
sensory function
In our study, we assessed the sensory function below the
level of injury (hind paws) by measuring the mechanical
and thermal thresholds for supraspinally mediated escape
behavior. Using this method (in contrast to hindpaw with-
drawal reflex methods) we did not observe SCI-induced
hyperalgesia at the hindpaws (below-level), which is in line
with observations reported from other laboratories
[73,74]. We did, however, find significant improvement of
both SCI-induced mechanical and thermal hypoesthesia.It is important to note that the sensory thresholds did not
yet plateau at the end of the two-month survival period.
We speculate that an additional quantitative and qualita-
tive improvement in the sensory function would likely be
seen should a longer post-grafting interval be studied. In
addition to sensory tests, quantitative analysis of spinal
parenchymal markers indicative of developing (spinal)
hypersensitivity (that is, CGRP/GAP43, an indicator of ab-
errant sprouting of primary sensory neurons [43,70] and
Iba1 staining, a marker of microglia activation [44]) were
studied and showed a significant decrease in CGRP stain-
ing intensities in HSSC-treated animals if compared to
SCI controls. This suggests that the recovery/decrease in
sensory thresholds observed in our study is not a result of
aberrant sprouting or microglia activation. Consistent
with the observations from our study, previous studies
from other laboratories have demonstrated similar func-
tional and histopathologically-defined (that is, decrease in
CGRP staining around the injury site) improvements after
spinal grafting of fetal-tissue derived human or rodent
neural or glial-restricted precursors in several mouse or
rat spinal injury models [65,66,68-70,72,73].
Differentiation of grafted cells and mechanism of
HSSC-mediated therapeutic action
In our current study, a near pure population of nestin+
human fetal spinal stem cells were grafted intraspinally
at three days after contusion-induced spinal cord injury.
Analysis of the graft survival at two months after graf-
ting showed a dense population of grafted hNUMA+
cells in grafted previously trauma-injured regions. In
addition, numerous hNUMA+ cells which migrated out
of the graft in distances ranging between 2 to 3 mm
were also seen. Using human-specific antibodies against
Neuron Specific Enolase and synaptophysin (markers of
mature neurons), we have also shown that a majority of
grafted cells developed into a neuronal phenotype. Many
human specific synaptophysin+ boutons were found to
reside in the vicinity of host neurons.
Quantitative analysis of the host axon survival in the
injury epicenter showed no significant sparing effect in
HSSC-grafted SCI animals versus medium-injected or
untreated SCI animals. These data suggest that I) the
majority of, if not all, axons which succumb to patho-
logical processes resulting from secondary changes post
injury, such as edema or ischemia, were already lost or
irreversibly damaged at three days after trauma (that is,
the time point when the cells were grafted), or II) regional
cell grafting is not therapeutically effective in providing
acute neuroprotection.
Analysis of the neurotransmitter phenotype in grafted
cells showed the development of putative inhibitory
GABA-ergic synapses with host neurons. These data
show that the restoration of the local functional
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observed functional improvements. While under specific
pathological conditions (such as inflammatory or neuro-
pathic pain) spinal GABA can have excitatory effects due
to reduced expression of the potassium-chloride exporter
KCC2 [75,76], systematic experimental but also clinical
studies have demonstrated a potent anti-spasticity effect
after intrathecal treatment with the GABAB receptor
agonist baclofen, suggesting continuing inhibitory GABAB
receptor-mediated action [77,78]. In addition, we have re-
cently demonstrated an effective anti-spastic effect after
spinal parenchymal GAD65 (glutamate decarboxylase)
upregulation if combined with systemic tiagabine (GABA
uptake inhibitor) treatment in animals with spinal
ischemia-induced muscle spasticity [79]. Jointly, these data
suggest the anti-spasticity effect observed in our current
study can be mediated by a synaptically coupled GABA-
inhibitory effect. Accordingly, in our previous study using
the same cell line, we have demonstrated the development
of putative GABA-ergic synaptic contacts between grafted
neurons and persisting α-motoneurons of the host in a rat
spinal ischemia model. In the same animals, a significant
amelioration of spasticity was measured [29]. In a recent
study using electron microscopy analysis, we have con-
firmed the development of synaptic contacts with the host
neurons at nine months after intraspinal grafting of HSSC
in normal non-injured immunodeficient rats [30]. Si-
milarly, in a more recent study, the development of
functional contacts and restoration of axon potential
conductivity across the region of complete Th3 spinal
transection by grafted HSSC was seen [32].
In addition to restoration of the local motor circuitry, sig-
nificant amelioration of otherwise increased spinal CGRP
expression seen in non-treated SCI animals was measured
in SCI animals receiving spinal injections of HSSC. Consist-
ent with this observation, previous studies have demon-
strated that improvement of local spinal GABA-ergic tone,
as achieved by subcutaneous inoculation of a replication-
incompetent herpes simplex virus (HSV) encoding GAD67
gene in a Th13 spinal cord hemisection model, led to a
similar decrease in otherwise increased CGRP expression
[80]. Second, previous studies have shown that spinally
grafted HSSC show the expression of several trophic factors
(GDNF, BDNF, and VEGF) at two months after grafting in
SOD+ rats [60]. We speculate that the release of these
trophic factors can potentiate the sprouting of persisting
axons of the host below and above the injury and accelerate
the development of new synaptic contacts particularly at
longer post-grafting intervals.
Finally, we have demonstrated a near complete injury-
cavity filling effect by the grafted cells at two months
after grafting when the cells were grafted at three days
after injury. This was in contrast to media-injected ani-
mals which showed consistent and extensive rostro-caudal spinal cord cavitation. These data suggest that
early post injury cell grafting is desirable as it can ef-
fectively block the formation of the spinal cavity and
its expansion and related long-term secondary spinal
cord degeneration. A comparable cavity-filling effect
and prevention in the progression of syringomyelia has
been shown after spinal grafting of human embryonic or
fetal SSCs in human patients with progressive post-
traumatic syringomyelia [54,55,81].
It is important to note that the cavity-filling effect dem-
onstrated in our current study was achieved without the
use of any supporting matrices or additional topical
growth factor(s) delivery. In our preliminary study, we
have determined that while the density of grafted cells is
relatively low to fill the cavity-forming region, the grafted
cells continue to proliferate after grafting to the point
where a cavity is near completely filled with grafted cells
(unpublished data). The cell proliferation is inhibited once
the cavity is filled and after that the cells differentiate nor-
mally. That the cells do not develop into pre-neoplastic or
neoplastic cells has been assessed in a nine-month tumori-
genicity study with nude rats whose Th9 spinal cord seg-
ment was first injured by contusion (manuscript in
preparation). Similarly, using the same cell line as used in
our current study, we have previously reported a compar-
able low level of mitotic activity in grafted cells at six
weeks to nine months after grafting in naïve immunodefi-
cient rats or immunosuppressed minipigs [82].
Conclusions
In our current study, we demonstrate a functionally-
defined treatment effect after spinal grafting of human
GMP-grade fetal spinal stem cells in immunosuppressed
SD rats with previous L3 contusion injury. This treat-
ment effect was expressed as a significant improvement
in motor and sensory function (gait/paw placement,
stretch-induced muscle spasticity, and, mechanical and
thermal sensitivity). No significant differences were de-
tected in other CatWalk parameters, motor evoked poten-
tials, open field locomotor (BBB) score or ladder climbing
test. In addition, an effective filling of the trauma-induced
spinal cavity with grafted cells was seen in HSSC-treated
animals at two months after grafting. Jointly, these data
demonstrate that the use of this clinical grade NSI-
566RSC cell line with an already established favorable
clinical safety profile represents a potential cell candi-
date for cell replacement therapy in patients with pre-
vious spinal traumatic injury.
Additional files
Additional file 1: Figure S1A-D. Effect of spinal HSSC grafting on
locomotor function (BBB), foot stepping angle, ladder climbing test and
motor evoked potentials. A: Weekly measurement of the BBB scores
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y-axis) showed progressive recovery in both HSSC-grafted and control SCI
animals. While there was a trend toward better motor performance in
HSSC-grafted-animals, this effect was not significant for both scoring
systems. B: Single Frame Analysis showed a tendency towards regaining
normal foot stepping angles between the paw and floor (measured at
stance-phase initiation; see insert/drawing in B) in SCI-HSSC-treated
animals. However, the angles were not significantly improved if
compared to SCI controls. C: Using the ladder climbing test, we found a
significant decrease in the number of correct steps in SCI animals if
compared to naïve controls. No significant difference was seen between
SCI-control and SCI-HSSC-treated animals if analyzed at two months after
treatments. D: Motor Evoked Potentials recorded at baseline (that is,
before injury) and at eight weeks post injury showed a significant
decrease only for the SCI-control animals. No significant difference
between HSSC-grafted and control SCI animals was detected.
Additional file 2: Figure S2A-D. Quantitative analysis of axonal survival
in the epicenter of injury showed no significant differences between
SCI-control and SCI-HSSC-treated animals. A: Schematic diagram of the
axon counting design used in our current study. Axons were counted in
plastic osmium-stained sections in the dorsal, lateral and ventral funiculi
using ImageJ software. An example of the detection threshold to identify
individual axons in a selected field is shown in A2 and A3. B: Transverse
plastic section depicting a bilaterally distributed graft (red dashed line)
and completely filling the cavity created by previous spinal compression.
Note that the fusion of the graft with the host tissue is so advanced that
the border between the previous injury-evoked cavity and the graft is
difficult to delineate (red asterisks). C: An example of transverse spinal
cord section taken from an animal receiving media injection. An
extensive cavity occupying near completely the region of previous gray
matter can be seen. D: Quantification of axons in SCI-control and
SCI-HSSC-treated animals showed no significant differences if analyzed
in dorsal, lateral or ventral funiculi or if sub-divided into axons of different
caliber (S = small = 0.3 to 1.0 μm; M = medium = 1.0 to 2.5 μm;
L = large = 2.5 to 10 μm). (Scale Bars: A to C: 500 μm).Abbreviations
(b)FGF: (basic) fibroblast growth factor; (c)GMP: (clinical) good manufacturing
practice; (D)MEM: (Dulbecco’s) modified Eagle medium; (e)GFP: (enhanced)
green fluorescent protein; AL-ER: above-level escape response;
ALS: amytrophic lateral sclerosis; ANOVA: analysis of variance; BBB
score: Basso, Beattie, and Bresnahan locomotion score; BDNF: brain-derived
neurotrophic factor; CGRP: calcitonin gene-related peptide; CHAT: choline
acetyltransferase; DCX: double cortin; DH: dorsal horn; EGF: epidermal growth
factor; EMG (/RES): electromyograpy (/resistance response); FSA: foot
stepping angle; G: gauge; GABA: gamma-aminobutyric acid; GAD65 and
67: glutamate decarboxylase 65 and 67; GAP43: growth associated protein
43; GDNF: glial cell line-derived neurotrophic factor; hGFAP: human-specific
glial fibrillary acidic protein; hNSE: human-specific neuron specific enolase;
hNUMA: human-specific nuclear mitotic apparatus; HSSC: human fetal spinal
cord-derived neural stem cells; hSYN: human-specific SYNaptophysin; i.
m.: intramuscular; i.p.: intraperitoneal; Iba1: ionized calcium binding adaptor
molecule 1; IGF-1: insulin-like growth factor-1; IHC: immunohistochemical;
KCC2: potassium chloride cotransporter 2; L1: first lumbar vertebral segment;
L3: third lumbar spinal cord segment; L6: sixth lumbar spinal cord segment;
LF: lateral funiculus; MEP: motor evoked potentials; MPE: maximal possible
effect; MRI: magnetic resonance imaging; NeuN: neuronal nuclei; NGF: nerve
growth factor; NPC: neural precursor cell; Olig2: OLIGodendrocyte lineage
transcription factor; PBS: phosphate-buffered saline; PC: personal computer;
PFA: paraformaldehyde; RCHPP: rostro-caudal hindpaw positioning;
RHI: rump-height-index; ROI: region of interest; s.c.: subcutaneous; SCI: spinal
cord injury; SD: Sprague–Dawley; SEM: standard error of the mean;
SOD1: copper zinc superoxide dismutase 1; Th8: eighth thoracic vertebral
segment; USP: United States Pharmacopeial Convention; VEGF: vascular
endothelial growth factor.
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